Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Diabetes and the brain: i… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Diabetes and the brain: issues and unmet needs

Forskningsöversiktsartikel
Författare N. M. Bornstein
M. Brainin
A. Guekht
Ingmar Skoog
A. D. Korczyn
Publicerad i Neurological Sciences
Volym 35
Nummer/häfte 7
Sidor 995-1001
ISSN 1590-1874
Publiceringsår 2014
Publicerad vid Institutionen för neurovetenskap och fysiologi
Sidor 995-1001
Språk en
Länkar dx.doi.org/10.1007/s10072-014-1797-...
Ämnesord Diabetes, Cognitive impairment, Vascular dementia, Stroke, MODERATE ALZHEIMERS-DISEASE, CARDIOVASCULAR RISK-FACTORS, INTENSIVE, INSULIN THERAPY, PLACEBO-CONTROLLED TRIAL, CRITICALLY-ILL PATIENTS, VASCULAR DEMENTIA, COGNITIVE IMPAIRMENT, DOUBLE-BLIND, RANDOMIZED-TRIAL, ISCHEMIC-STROKE, Clinical Neurology, Neurosciences
Ämneskategorier Diabetologi, Neurovetenskaper, Neurologi

Sammanfattning

Diabetes mellitus (DM) is associated with an increased risk of mild cognitive impairment, dementia and stroke. The association between DM and dementia appears to be stronger for vascular cognitive impairment than for Alzheimer's disease, suggesting cerebrovascular disease may be an important factor in cognitive impairment in DM. Although the exact mechanisms by which DM affects the brain remain unclear, changes to brain vasculature, disturbances of cerebral insulin signaling, insulin resistance, glucose toxicity, oxidative stress, accumulation of advanced glycation end products, hypoglycemic episodes, and alterations in amyloid metabolism may all be involved. Cognitive impairment and dementia associated with DM may also be mediated via vascular risk factors, in particular brain ischemia, the occurrence of which can have an additive or synergistic effect with concomitant neurodegenerative processes. To date, no drug has been approved for the treatment of vascular dementia and there are no specific pharmacological treatments for preventing or reducing cognitive decline in patients with DM. Most focus has been on tighter management of vascular risk factors, although evidence of reduced cognitive decline through reducing blood pressure, lipid-lowering or tighter glycemic control is inconclusive. Tailored, multimodal therapies may be required to reduce the risk of cognitive dysfunction and decline in patients with DM. The use of pleiotropic drugs with multimodal mechanisms of action (e.g., cerebrolysin, Actovegin) may have a role in the treatment of cognitive dysfunction and their use may warrant further investigation in diabetic populations.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?